On September 9, 2026 Aktis Oncology, Inc. ("Aktis"), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies, reported that Matthew Roden, Ph.D., President and Chief Executive Officer of Aktis Oncology, will participate in the following investor conferences in September.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Morgan Stanley 24th Annual Global Healthcare Conference
Date & Time: Wednesday, September 16, 2026, at 8:30 a.m. ET
Location: New York, NY
Oppenheimer 4th Annual Targeted Radiopharmaceutical Therapies in Oncology Summit
Date: Thursday, September 17, 2026
Location: New York, NY
A live webcast of the Morgan Stanley presentation may be accessed via the Investors section of the Aktis website at investors.aktisoncology.com. An archived replay of the event will be available on the website for approximately 90 days following the conference.
About Aktis’ Radioconjugate Platform
Aktis has developed a proprietary, isotope-agnostic miniprotein radioconjugate platform to selectively deliver the tumor-killing properties of radioisotopes to targeted tumors. Aktis’ therapeutic miniprotein radioconjugates are designed to maximize anticancer activity through high tumor penetration coupled with internalization and retention in cancer cells, while rapidly clearing from normal organs and tissues. The Aktis platform further enables clinicians to visualize and verify target engagement with imaging isotopes prior to exposure to therapeutic radioisotopes. Leveraging this platform, and its patient-first end-to-end clinical supply chain built for resiliency and scalability, Aktis is advancing a pipeline of next-generation targeted radiopharmaceuticals to address the unmet needs of patients across a broad spectrum of solid tumors.
(Press release, Aktis Oncology, SEP 9, 2026, View Source [SID1234670678])